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ABSTRACT 
Probability based criteria is in the study design where many research scientists prefer to understand the power and 
probability of taking a new drug forward across the whole range of possible true treatment effects, rather than 
focusing on one particular value to power the study.    Examples will be used in this paper to show how to compute 
probability using the SAS®/STAT procedure PROC MIXED.   Particular emphasis is given to the application on 
efficacy analysis, including the comparison to classical hypothesis testing. The application on safety analysis is also 
discussed. 
INTRODUCTION 
Probability based criteria in early phase drug development is based on the idea that the new drugs might do 
something but they might not be as good as the comparators on the market.  It will help us to make correct decision 
before we start a study rather than making up the decision at the end of the study.  The first example in this paper will 
explain how to set up the criteria on efficacy. The first part is to show separation to placebo, as in a standard power 
calculation. The second part is a harder hurdle designed to give confidence we are at least as good as standard of 
care. The second example in this paper will discuss the probability based on safety. 
DATA SIMULATION 
Suppose we have a simple clinical trial data with a sample of 50 subjects randomly assigned to placebo and a new 
drug with a 1:1 randomization ratio.  The outcome is efficacy measured at four time points.  The first measurement is 
a pre-dose baseline assessment which is followed by three post-dose repeated measurements.  The following code 
produces the simulated efficacy data:                                                                                                                                 
/** introduce variability **/    
data sample;                                                                                                                             
  do subjid=101 to 110, 201 to 210, 301 to 310, 401 to 410, 501 to 510;     
    if uniform(12345)>=0.5 then treatment='pl'; 
      else treatment='dx';                                                                                                                                                                                                                               
    do month=3, 2, 0, 1;   
      result=10+0.5*(normal(6789));   
      if month>0 and treatment='dx' then result=result-1.075;        
      site=round(subjid,100.); 
      output;                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    end; 
  end;                                                                                                                                   
run; 
 
/** derive change and baseline variables **/    
proc sql; 
  create table indata as  
    select a.site, a.subjid, a.treatment, a.month, 
           a.result-b.result as change, b.result as baseline 
      from sample(where=(month>0)) as a, sample(where=(month=0)) as b  
      where a.site=b.site and a.subjid=b.subjid  
      order by site, subjid, month; 
quit; 
  
When we apply a simple mixed model repeated measurement (MMRM) analysis on the simulated efficacy data, the 
SAS®/STAT procedure PROC MIXED provides options to output least-squares means and difference of least-
squares means with the ODS OUTPUT statement.    
The following code creates the data sets LSM1 (least-squares means) and DIFF1 (difference of least-squares 
means): 
ods output lsmeans=lsm1 diffs=diff1; 
proc mixed data=indata;   
    class site subjid month treatment;  
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    model change=site treatment month treatment*month baseline baseline*month/ddfm=kr; 
    repeated month/subject=subjid type=un; 




The data produced by PROC MIXED code above is stored in the work data sets LSM1 and DIFF1, and they can be 
combined to produce the following typical hypothesis testing report:  
 
 ----------------------------------------------------------------------                                                              
            Placebo            New Drug         Difference to Placebo    
       ------------------ ------------------ -------------------------- 
 Month  LS Mean(90% CI)    LS Mean(90% CI)    LS Mean(90% CI)   p-value  
 ---------------------------------------------------------------------- 
   1   -0.07(-0.24,0.09)  -1.01(-1.18,-0.84) -0.94(-1.18,-0.70)  <0.001  
   2   -0.02(-0.16,0.11)  -1.04(-1.18,-0.90) -1.01(-1.21,-0.82)  <0.001  
   3    0.08(-0.07,0.24)  -1.20(-1.36,-1.04) -1.28(-1.50,-1.06)  <0.001  
 ----------------------------------------------------------------------                                                              
 
Table 1. Typical Hypothesis Testing Report 
In the analysis plan, we assume that: 
 
“The sample size of 50 has been chosen to give 80% power to detect a 1-point difference from placebo using a 1- 
sided test with a 0.1 significance level.”  
 
Although there is a significant treatment difference from placebo in output 1, the significance test is 2-sided and 
compares against 0, not 1.  
COMPUTING PROBABILITY BASED CRITERIA FOR EFFICACY APPLICATIONS  
The choice to set up the probability based criteria usually depends on our knowledge about the compound, our 
clinical plan and the competition. In some therapeutic areas, the efficacy should be better than standard of care, so 
we can choose the first criteria to be “new drug is better than placebo with at least 90% probability” and the second 
criteria to be “new drug is better than standard of care with at least 67% probability”.  In other therapeutic areas, the 
efficacy is equivalent with the standard of care, but the new drug has a better safety profile and less side effects. In 
the second case we can choose the first criteria to be “new drug is better than placebo with at least 90% probability” 
and the second criteria to be “new drug is better than standard of care with at least 33% probability”.    
In this example, if the efficacy is equivalent with the standard of care, and the standard of care is about 1 reduction 
from the placebo, then following 2 part criteria would have been used: 
 
Part 1 Criteria: New drug has a reduction > 0 with at least 90% probability 
Part 2 Criteria: New drug has a reduction > 1 with at least 33% probability 
Let X be the difference between the new drug and placebo, the probability is calculated as: 
 P(X<x) = probt[(x-d)/se, df]  
where d is the estimated difference, se is the standard error of the estimated difference and df is the degrees of 
freedom associated with this difference.  
So the following assignments would set up the 2 part criteria: 
 
Part 1 Criteria: P (new drug – placebo < 0) = probt ((0 – d) / se, df) or 
 
          P (X<0) = prob0 = probt(-tvalue, df);   
 
Part 2 Criteria: P (new drug – placebo < -1) = probt ((-1 – d) / se, df) or 
 
          P (X<-1) = prob1= probt(t1,df);    where t1 = (-1-estimate)/se;    
 
 
The following is the completed data step to create data set DIFF2: 




     set diff1(where=( month=_month and  _treatment='pl'));  
     cdiff=compress(put(estimate,6.2)||"("||put(lower,6.2)||","||put(upper,6.2)||")"); 
     pvalue=probt; 
     prob0=compress(put(probt(-tvalue, df), 6.3));  
     t1=(-1-estimate)/stderr;  
     prob1=compress(put(probt(t1,df), 6.3)); 
 run; 
 
The data set DIFF2 combined with LSM1 would have the following new report: 
 
 ---------------------------------------------------------------------------------------------                                          
                                                                         Probability treatment 
            Placebo            New Drug         Difference to Placebo      reduction > x(unit)    
       ------------------ ------------------ --------------------------- --------------------- 
 Month  LS Mean(90% CI)    LS Mean(90% CI)    LS Mean(90% CI)   p-value     x=0        x=1     
 --------------------------------------------------------------------------------------------- 
   1   -0.07(-0.24,0.09)  -1.01(-1.18,-0.84) -0.94(-1.18,-0.70)  <0.001    1.000      0.334    
   2   -0.02(-0.16,0.11)  -1.04(-1.18,-0.90) -1.01(-1.21,-0.82)  <0.001    1.000      0.549    
   3    0.08(-0.07,0.24)  -1.20(-1.36,-1.04) -1.28(-1.50,-1.06)  <0.001    1.000      0.980    
 ---------------------------------------------------------------------------------------------                                          
 
Table 2. Report Including the Probability Based Criteria on Efficacy 
By achieving criteria 1, we are at least 90% sure that the new drug has some improvement over placebo.  And by 
achieving criteria 2, we are at least 33% sure the new drug are better than standard of care or similar to competitor in 
efficacy. This means we can go forward with more confidence that we are in the region of what‟s already on the 
market, but further consideration is required for a favorable safety profile. 
COMPUTING PROBABILITY BASED CRITERIA FOR SAFETY APPLICATIONS  
In setting up probability based criteria for safety application, it is a little different than looking for confidence for 
efficacy. For example, we are looking for confidence we do not have an increase in a safety outcome with this class 
of drugs. 
Suppose a drug with this safety parameter increase >5 is not good. To move forward to next phase of drug 
development, we want to achieve „New drug effect on this safety parameter is <5 compared to placebo with at least 
60% probability‟, so we have 
P (new drug – placebo < 5) = probt ((5 – d) / se, df) or  
 
P (X<5) = prob5 = probt(t5,df);    where t5 = (5-estimate)/se;    
 
By using following simulation safety data steps and PROC MIXED:  
 
data sample;                                                                                                                                
  do subjid=101 to 110, 201 to 210, 301 to 310, 401 to 410, 501 to 510;     
    if uniform(12345)>=0.5 then treatment='pl'; 
      else treatment='dx';                                                                                                                                                                                                                             
    do day=0,1,2,3,4,5,6,7,14,21,28;                 
      result=100+7.5*normal(6789);  
      site=round(subjid,100.); 
      output;                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    end; 




  create table indata as  
    select a.site, a.subjid, a.treatment, a.day, 
    a.result-b.result as change, b.result as baseline 
      from sample(where=(day>0)) as a, sample(where=(day=0)) as b  
      where a.site=b.site and a.subjid=b.subjid  
      order by site, subjid, day; 
quit; 
  
Probability Based Criteria in Early Phase Drug Development, continued 
4 
 
ods output lsmeans=lsm1 diffs=diff1; 
proc mixed data=indata;   
class site subjid day treatment;  
model change=site treatment day treatment*day baseline baseline*day/ddfm=kr; 
  repeated day/subject=subjid type=un; 





set diff1(where=( day=_day and  _treatment='pl'));                
cdiff=compress(put(estimate,6.2)||"("||put(lower,6.2)||","||put(upper,6.2)||")"); 
     pvalue=probt;       
     t5=(5-estimate)/stderr;  
     prob5=compress(put(probt(t5,df), 6.3)); 
run; 
 
The data set DIFF2 combined with LSM1 would have the following new report: 
 
 -------------------------------------------------------------------------------------------                                          
            Placebo            New Drug         Difference to Placebo      Probability that   
       ------------------ ------------------ ---------------------------     Difference to    
  Day   LS Mean(90% CI)    LS Mean(90% CI)    LS Mean(90% CI)   P-value   Placebo < 5(unit)   
 ------------------------------------------------------------------------------------------- 
   1   -0.01(-2.84,2.82)  -0.53(-3.36,2.30)  -0.52(-4.55,3.50)    0.829         0.987         
   2   -0.06(-2.19,2.06)  -0.64(-2.76,1.49)  -0.57(-3.60,2.45)    0.752         0.998         
   3   -1.22(-3.26,0.82)   1.00(-1.04,3.05)   2.22(-0.69,5.14)    0.207         0.942         
   4   -3.82(-6.12,-1.51) -1.12(-3.42,1.19)   2.70(-0.58,5.98)    0.174         0.877         
   5   -3.27(-5.89,-0.65)  0.86(-1.75,3.48)   4.13(0.41,7.86)     0.069         0.651         
   6    0.62(-1.84,3.07)  -2.33(-4.78,0.13)  -2.94(-6.44,0.56)    0.165         1.000         
   7   -0.40(-2.91,2.10)   0.42(-2.09,2.92)   0.82(-2.75,4.39)    0.701         0.972         
  14   -1.57(-3.97,0.82)  -0.80(-3.19,1.60)   0.78(-2.64,4.19)    0.704         0.978         
  21   -0.92(-3.22,1.39)  -1.85(-4.15,0.46)  -0.93(-4.21,2.35)    0.637         0.998         
  28    0.30(-2.03,2.62)  -0.33(-2.66,1.99)  -0.63(-3.94,2.68)    0.751         0.997         
 ------------------------------------------------------------------------------------------                                          
 
 
Table 3. Report Including the Probability Based Criteria on Safety   
CONCLUSION 
Probability based criteria have become more useful in the study design for research scientists in early phase drug 
development, because they provide a straightforward statistical framework that not only helps the study team to 
communicate and understand the new drug, but also enables the management team to make the correct decision.  I 
hope this paper is useful to statistical analysts and others who perform statistical analysis duties in clinical trials or 
clinical research.  
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